EMEND (Merck Sharp & Dohme Corp.)
Welcome to the PulseAid listing for the EMEND drug offered from Merck Sharp & Dohme Corp.. This Neurokinin 1 Antagonists [MoA],Substance P/Neurokinin-1 Receptor Antagonist [EPC],Cytochrome P450 3A4 Inhibitors [MoA],Cytochrome P450 2C9 Inducers [MoA],Cytochrome P450 3A4 Inducers [MoA] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
| LABELER NAME / MANUFACTURER: | Merck Sharp & Dohme Corp. |
| NON-PROPRIETARY NAME: | FOSAPREPITANT DIMEGLUMINE |
| SUBSTANCE NAME: | FOSAPREPITANT DIMEGLUMINE |
| TYPE: | HUMAN PRESCRIPTION DRUG |
| PHARMA CLASS: | Neurokinin 1 Antagonists [MoA],Substance P/Neurokinin-1 Receptor Antagonist [EPC],Cytochrome P450 3A4 Inhibitors [MoA],Cytochrome P450 2C9 Inducers [MoA],Cytochrome P450 3A4 Inducers [MoA] |
| ROUTE: | INTRAVENOUS |
| DOSAGE FORM: | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION |
| MARKETING CATEGORY NAME: | NDA |
| START MARKETING DATE: | 2017-02-03 |
| END MARKETING DATE: | 0000-00-00 |
EMEND HUMAN PRESCRIPTION DRUG Details:
| Item Description | EMEND from Merck Sharp & Dohme Corp. |
| LABELER NAME: | Merck Sharp & Dohme Corp. |
| DEA SCHEDULE: |
|
| ACTIVE STRENGTH: | 150(mg/5mL) |
| START MARKETING DATE: | 2017-02-03 |
| END MARKETING DATE: | 0000-00-00 |
| PRODUCT ID: | 0006-3061_8ae181cc-f15d-436d-80aa-e880e217ddeb |
| PRODUCT NDC: | 0006-3061 |
| APPLICATION NUMBER: | NDA022023 |
Other FOSAPREPITANT DIMEGLUMINE Pharmaceutical Manufacturers / Labelers:
